Aluminum Hydroxide Adjuvants Vaccine Linkers
- Summary
- Purdue University researchers have developed a simple chemical reagent that attaches a phosphate group to specific sites on the protein, but does not change the overall structure. This method can work with a wide variety of antigens and could lead to vaccines that are more effective for many pathogens.
- Technology Benefits
- Does not modify protein structureWorks with many varieties of antigensUses adjuvant with excellent safety record
- Technology Application
- Medical/HealthcarePharmaceutical industryVaccines
- Detailed Technology Description
- Richard BorchPurdue Medicinal Chemistry and Molecular Pharmacology
- Countries
- United States
- Application No.
- None
- *Abstract
-
- *Background
- Vaccines typically work by exposing the body to an antigen, which is either a weakened form of a microorganism or a toxin that it creates. This exposure stimulates an immune system response that lets the body recognize the pathogen so that it can more easily recognize and destroy it in the future. Sometimes, the proteins used in the vaccine are bound to an adjuvant (commonly aluminum hydroxide), which acts as an irritant to enhance the immune response to the antigen while reducing the amount of foreign material that must be injected. To attach the aluminum hydroxide to the protein, a phosphate group is first attached to the protein. Phosphate groups have a high electrostatic affinity for aluminum hydroxide, so they readily bond to each other. However, current techniques for attaching the phosphate group to a protein have the unintended effect of changing the structure of the protein.
- *IP Issue Date
- None
- *IP Type
- Other Patent
- *Stage of Development
- Proof of Concept
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipRichard BorchPurdue Medicinal Chemistry and Molecular Pharmacology
- Country/Region
- USA
For more information, please click Here
